Clinical and preclinical studies have shown that the HER2/HER3/Akt pathway is highly implicated in trastuzumab resistance, where heterodimerization of HER family members and existence of p95HER2 is associated with breast cancer treatment [6, 50]. The gene discussed is ERBB2; the disease is breast carcinoma.